Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccolini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M., Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation., «EUROPEAN JOURNAL OF HAEMATOLOGY», 2008, 80, pp. 31 - 36 [articolo]
Rapezzi C; Riva L; Quarta CC; Perugini E; Salvi F; Longhi S; Ciliberti P;
Pastorelli F; Biagini E; Leone O; Cooke RM; Bacchi-Reggiani L; Ferlini A; Cavo M; Merlini G; Perlini S; Pasquali S; Branzi A, Gender-related risk of myocardial involvement in systemic amyloidosis, «AMYLOID», 2008, 15(1), pp. 40 - 48 [articolo]
Ludwig H; Durie BG; Bolejack V; Turesson I; Kyle RA; Blade J; Fonseca R;
Dimopoulos M; Shimizu K; San Miguel J; Westin J; Harousseau JL; Beksac M;
Boccadoro M; Palumbo A; Barlogie B; Shustik C; Cavo M; Greipp PR; Joshua D; AttalM; Sonneveld P; Crowley J., Myeloma in patients younger than age 50 years presents with more favorable
features and shows better survival: an analysis of 10 549 patients from the
International Myeloma Working Group., «BLOOD», 2008, 115, pp. 4039 - 4047 [articolo]
Palumbo A; Bringhen S; Liberati AM; Caravita T; Falcone A; Callea V; MontanaroM; Ria R; Capaldi A; Zambello R; Benevolo G; Derudas D; Dore F; Cavallo F; Gay F;Falco P; Ciccone G; Musto P; Cavo M; Boccadoro M., Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial, «BLOOD», 2008, 112, pp. 3107 - 3114 [articolo]
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, JoshuaD, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S,Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ,Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA;International Myeloma Working Group., Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma., «LEUKEMIA», 2008, 22, pp. 414 - 423 [articolo]
Cavo M.; Pallotti M.C.; Pantani L.; Petrucci A.; Brioli A.; Terragna C.; Testoni N.; Marzocchi G.; Durante S.; Ceccolini M.; Perrone G.; Tacchetti P.; Zamagni E.; Tosi P.; Baccarani M., Proteasome inhibitors: Bortezomib in multiple myeloma, «HEMATOLOGY MEETING REPORTS», 2008, 2, pp. 127 - 132 [articolo]
SanMiguel J; Facon T; Cavo M., Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice., «CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY», 2008, 6, pp. s4 - s10 [articolo]
CAVO M; ATTAL M; GERTZ MA; GIRALT S; LUDWIG H; MORGAN GJ; ANDERSON KC., The current landscape of multiple myeloma treatment, «LEUKEMIA RESEARCH», 2008, 32, pp. S1 - S2 [articolo]
Hussein M.A.;Vrionis F.D.;Allison R.;Berenson J.;Berven S.;Erdem E.;Giralt S.;Jagannath S.;Kyle R.A.;LeGrand S.;Pflugmacher R.;Raje N.;Rajkumar S.V.;Randall R.L.;Roodman D.;Siegel D.;Vescio R.;Zonder J.;Durie B.G.;International Myeloma Working Group [..; Cavo M; ..], The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement., «LEUKEMIA», 2008, 22, pp. 1479 - 1484 [articolo]
Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S., 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone., «IN VIVO», 2008, 22, pp. 513 - 517 [articolo]
Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M., A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma., «HAEMATOLOGICA», 2007, 92(1), pp. 50 - 55 [articolo]
Cavo M, Current status of bortezomib in the treatment of multiple myeloma., «CURRENT HEMATOLOGIC MALIGNANCY REPORTS», 2007, 2, pp. 128 - 137 [articolo]
C. Terragna; M. Renzulli; D. Remondini; E. Tagliafico; E. Roncaglia; P. Tosi; E. Zamagni; P. Tacchetti; G. Perrone; M. Ceccolini; G. Martinelli; M. Baccarani; M. Cavo, Gene expression profiling (gep) of myeloma (MM) cells to predict attainment near complete response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed MM, in: , «BLOOD», 2007, 108(atti di: 48th American Society for Hematology Annual Meeting, Orlando, Florida, December 9-12, 2006) [atti di convegno-abstract]
Cavo M., Le gammapatie monoclonali., in: TURA S., Corso di Malattie del Sangue e degli Organi Emolinfopoietici., BOLOGNA, Esculapio, 2007, pp. 262 - 287 [capitolo di libro]
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA., Neuropathy in multiple myeloma treated with thalidomide: a prospective study., «NEUROLOGY», 2007, 69, pp. 573 - 581 [articolo]
